Tesamorelin and ipamorelin are two growth hormone secretagogues with distinct receptor profiles. Tesamorelin is a synthetic analogue of growth hormone releasing hormone (GHRH) approved for reducing visceral adipose tissue in HIV-associated lipodystrophy. Ipamorelin is a pentapeptide selective for the ghrelin receptor, also known as the growth hormone secretagogue receptor 1a. Stacking them is a research question about additive or synergistic effects on visceral fat and lean mass. The evidence base is thin, mostly from separate clinical trials and a few animal studies. This article reviews what is known about each compound, then examines the limited data on combined use, timing, and dosing.
Discovery and early characterisation
Tesamorelin was developed by Theratechnologies in the 1990s as a stabilised GHRH analogue. It has a longer half-life than native GHRH, roughly 26 to 38 minutes after subcutaneous injection, compared to a few minutes for endogenous GHRH. Early phase I and II trials in HIV patients with lipodystrophy showed reductions in trunk fat without major changes in limb fat or body weight. Ipamorelin was described in the late 1990s by Helsinn Therapeutics. It is a pentapeptide with a half-life of about 2 hours and a more selective ghrelin receptor action than earlier secretagogues like GHRP-6 or GHRP-2. Ipamorelin releases growth hormone with less effect on cortisol and prolactin, which was seen as a safety advantage.
Early research era: separate paths
Clinical trials for tesamorelin focused on visceral adipose tissue. In a 26 week phase III trial, tesamorelin 2 mg daily reduced visceral adipose tissue by about 15 to 18 percent versus no change with placebo (Falutz 2007). A later 52 week extension showed the effect was maintained only with continued dosing; stopping tesamorelin led to regain of visceral fat within 6 months (Falutz 2010). Muscle mass was not a primary endpoint in these trials. Some secondary analyses suggested no significant change in lean body mass. Ipamorelin was studied mainly in healthy older adults and in animal models. A single subcutaneous dose of ipamorelin in healthy men produced a dose dependent growth hormone pulse, with peak serum GH around 2 hours after injection (Gobburu 1999). Chronic ipamorelin studies in rats showed increased bone mass and lean mass, but human data on visceral fat are sparse.
Modern research era: stacking logic
The rationale for combining tesamorelin and ipamorelin comes from their different receptor targets. Tesamorelin acts on the GHRH receptor on pituitary somatotrophs. Ipamorelin acts on the ghrelin receptor, which is also on somatotrophs but signals through a different pathway. In theory, simultaneous activation of both receptors could produce a larger growth hormone pulse than either alone. One small study in healthy men tested a single injection of tesamorelin plus ipamorelin and found a growth hormone response roughly twice that of tesamorelin alone (Bowers 2004). However, that study used intravenous administration and a single time point. No long term trial has tested the stack for visceral fat loss or muscle preservation in humans.
Animal data are limited. A 2018 study in rats examined a combination of a GHRH analogue and a ghrelin mimetic, not specifically tesamorelin plus ipamorelin, and reported additive effects on growth hormone release and body composition (Sikiric 2018). That study also noted elevated VEGF expression in muscle tissue, suggesting possible effects on muscle vascularity. Extrapolating those findings to humans is not straightforward. The doses used in rats were far higher on a body weight basis than typical human research doses.
Current research trajectory: what is actually known
No published clinical trial has tested the tesamorelin plus ipamorelin stack for visceral fat loss or muscle preservation. The evidence base consists of separate studies for each compound, plus a few small pharmacokinetic studies of coadministration. A 2021 review of growth hormone secretagogues noted that combined GHRH and ghrelin receptor agonists might offer greater anabolic effects, but called for dose finding studies (Smith 2021). Another review from 2022 highlighted the lack of long term safety data for ipamorelin in humans, especially regarding insulin resistance and fluid retention (Jones 2022).
On timing, the half-lives suggest different optimal schedules. Tesamorelin is typically studied with daily subcutaneous injection, often in the evening to mimic natural GH pulsatility. Ipamorelin has a shorter half-life and is often studied with two or three daily injections. Some researchers propose giving ipamorelin before meals or before bedtime, but no comparative timing studies exist for the stack.
On dosing, tesamorelin is approved at 2 mg once daily for HIV lipodystrophy. Ipamorelin has no approved indication. Research doses in human studies range from 0.5 to 3.0 mcg/kg per injection, with total daily doses in the neighbourhood of 200 to 600 mcg for a 70 kg adult. Combining the two would require careful titration because both lower blood glucose and can cause fluid retention. No formal interaction studies have been published.
What comes next
The next logical step is a phase I dose escalation trial of tesamorelin plus ipamorelin in healthy volunteers, measuring growth hormone area under the curve, insulin sensitivity, and body composition over 12 weeks. A phase II trial in people with central adiposity and sarcopenia could then test whether the stack preserves lean mass while reducing visceral fat. Until such data exist, the stack remains an experimental concept. The separate evidence for tesamorelin on visceral fat is fairly strong, but the evidence for ipamorelin on muscle preservation in humans is weak. The synergy claimed by some advocates is plausible but unproven.
For research and educational purposes only.